Sector News

Trump's hiring freeze hurts an already-struggling FDA: expert

January 30, 2017
Life sciences

President Donald Trump’s move to instate a federal hiring freeze quickly set off concerns in the pharmaceutical industry as experts said a handcuffed FDA might not be able to keep up with an influx of drug applications.

Following Trump’s order to halt hiring on Monday, former FDA official Bob Pollock noted in a blog post that the FDA is already struggling to “keep pace” and meet its deadlines.

“While hiring freezes and restrictions of new regulations are not uncommon during a change of administration, with the new President’s pledge to reduce government and cut regulations by 75%, we could be in for a long, unpleasant haul,” he wrote.

A White House spokesperson told Regulatory Focus the freeze “has exemptions for public safety, which certainly could include public health.” Pollock’s opinion is that the exemption won’t include FDA staff.

The FDA is set to receive 1,600 abbreviated new drug applications this fiscal year, Pollock said. Already, the generics industry, which counts on strong FDA staffing to green light cheap alternatives to branded drugs, has voiced its concerns.

In total, there are 4,000 generic applications pending at the FDA, according to GPhA, and 850 open positions at the agency’s Center for Drug Evaluation and Research. Among that group are 150 openings for generic drug reviewers.

“A fully resourced FDA is critical to reducing the backlog and making sure that patients have timely access to medicines,” GPhA said in a statement. “The agency itself has recognized the need for more resources to expedite the approval of generics and biosimilars.”

What’s more, the FDA will collect user fees as normal during the freeze, GPhA said. Those “should be fully available for their dedicated uses, including hiring,” according to the group’s statement.

GPhA has regularly argued that increased competition from generics are a solution to the United States’ drug cost woes, with CEO Chip Davis saying last fall that egregious price hikes were rare among copycats. He pointed out that specialty drugs accounted for 31.8% of spending on 1% of the population in 2014, with the spending figure headed to 50% by 2018. Alternatively, generics make up 88% of prescriptions but account for 28% of costs, he said.

For its part, pharma’s trade group said it’s still reviewing the executive order. The group described the FDA as the “gold standard.”

“A stable and sustainable workforce is crucial to the agency’s ability to keep pace with scientific advances in biopharmaceutical drug development while ensuring safe and effective medicines reach patients in a timely manner,” PhRMA said in a statement.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend